The Use of Ascorbic Acid in Adjunctive Treatment for Schizophrenia—Current State of Knowledge
Life · 28.06.2024 · 14 (7) · 828
DOI: 10.3390/life14070828 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 28.06.2024. Verfasst von Patrycja Piłat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Students Scientific Association, Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 K…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Schizophrenia is a mental illness characterized by disturbances in the perception of reality, thinking, emotions, and social functioning. This significantly impacts the quality of life of patients and leads to long-term disability. Despite advances in understanding its pathogenesis and treatment, schizophrenia remains a clinical challenge, especially due to the diversity of its symptoms and the complexity of its mechanisms. Schizophrenia is associated with abnormal functioning of the dopaminergic system, disturbances in glutamatergic neurotransmission, and oxidative stress in the brain. In recent years, there has been increasing interest in optimizing the treatment of mental disorders. The potential use of ascorbic acid, or vitamin C, in the therapy of schizophrenia could bring substantial benefits to patients. Ascorbic acid exhibits antioxidant and neuroprotective properties, suggesting its potential efficacy in reducing brain oxidative stress and improving neurotransmission. Additionally, there have been reports of its positive effects on psychotic symptoms and its potential in reducing the side effects of antipsychotic drugs. In this review article, we present the current state of knowledge on the potential use of ascorbic acid in the treatment of schizophrenia as an adjunct to standard pharmacological therapy. We analyze existing clinical studies and the mechanisms of action of vitamin C, suggesting its promising role as an adjunctive therapy in the treatment of schizophrenia. These insights, though not yet widely disseminated, may be significant for the further development of therapeutic strategies for this mental illness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Students Scientific Association, Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
- Department of Psychoprophylaxis, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
- Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
ORCID-Profile: Joanna Smolarczyk, Magdalena Piegza
Zitieren
APA
Piłat, P., Nikel, K., Smolarczyk, J., & Piegza, M. (2024). The Use of Ascorbic Acid in Adjunctive Treatment for Schizophrenia—Current State of Knowledge. Life, 14(7), 828. https://doi.org/10.3390/life14070828
Vancouver
Piłat P, Nikel K, Smolarczyk J, Piegza M. The Use of Ascorbic Acid in Adjunctive Treatment for Schizophrenia—Current State of Knowledge. Life. 2024;14(7):828. doi:10.3390/life14070828
BibTeX
@article{Piat2024,
author = {Piłat, Patrycja and Nikel, Kamil and Smolarczyk, Joanna and Piegza, Magdalena},
title = {The Use of Ascorbic Acid in Adjunctive Treatment for Schizophrenia—Current State of Knowledge},
journal = {Life},
year = {2024},
volume = {14},
number = {7},
pages = {828},
doi = {10.3390/life14070828}
}
EUVIMED